Advertisement
Screener

VivoSim Labs, Inc. (VIVS) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.8 / 5 stars · 31/86 Roast Me

VivoSim Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

VivoSim Labs, Inc. (VIVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12

  • VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
  • VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 629.00 shares.
  • VivoSim Labs, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 1.92K shares, a 72.18% decline year-over-year.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month
2026-06-300.00 shares
10-Q · filed 2026-08-12
2025-12-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-11
629.00 shares
derived: sum of 2 quarters · filed 2026-02-11
2.55K shares
10-Q · filed 2026-02-11
2025-09-30629.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06
2.55K shares
10-Q · filed 2025-11-06
2025-06-301.92K shares
10-Q · filed 2025-08-12
2024-12-3169.49K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-19
69.49K shares
derived: sum of 2 quarters · filed 2025-02-19
76.40K shares
10-Q · filed 2025-02-19
2024-09-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-08
6.91K shares
10-Q · filed 2024-11-08
2024-06-306.91K shares
10-Q · filed 2024-08-05
2023-12-3118.11K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08
593.38K shares
10-Q · filed 2024-02-08
2023-09-30575.28K shares
10-Q · filed 2023-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
Silexion Therapeutics Corp (SLXN)$0.001B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70